190 related articles for article (PubMed ID: 23925046)
1. Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.
Martins LR; Lúcio P; Melão A; Antunes I; Cardoso BA; Stansfield R; Bertilaccio MT; Ghia P; Drygin D; Silva MG; Barata JT
Leukemia; 2014 Jan; 28(1):179-82. PubMed ID: 23925046
[No Abstract] [Full Text] [Related]
2. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Prins RC; Burke RT; Tyner JW; Druker BJ; Loriaux MM; Spurgeon SE
Leukemia; 2013 Oct; 27(10):2094-6. PubMed ID: 23900138
[No Abstract] [Full Text] [Related]
3. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia.
Kriachok IA
Exp Oncol; 2012 Dec; 34(4):378-80. PubMed ID: 23303003
[No Abstract] [Full Text] [Related]
5. Chronic lymphocytic leukemia: where are we and where are we going?
Ujjani C; Cheson BD
Expert Opin Pharmacother; 2012 Aug; 13(12):1675-7. PubMed ID: 22768797
[No Abstract] [Full Text] [Related]
6. CX-5461 inhibits RNA Pol I in blood cancers.
Cancer Discov; 2014 Dec; 4(12):OF5. PubMed ID: 25477122
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine approved for use in chronic lymphocytic leukemia.
Oncology (Williston Park); 1991 Jun; 5(6):20. PubMed ID: 1831638
[No Abstract] [Full Text] [Related]
8. Optimizing drug dosing for the treatment of chronic lymphocytic leukemia.
Jain N
Clin Adv Hematol Oncol; 2019 Jun; 17(6):330-331. PubMed ID: 31437134
[No Abstract] [Full Text] [Related]
9. The evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.
Lamanna N
Clin Adv Hematol Oncol; 2016 Oct; 14(10):756-758. PubMed ID: 27930625
[No Abstract] [Full Text] [Related]
10. B-cell receptor inhibitors in chronic lymphocytic leukemia.
Brown JR
Clin Adv Hematol Oncol; 2013 Jun; 11(6):362-4. PubMed ID: 24472805
[No Abstract] [Full Text] [Related]
11. Response criteria with fludarabine therapy in chronic lymphocytic leukemia.
Rai KR
Blood; 1994 Feb; 83(3):875-6. PubMed ID: 8298148
[No Abstract] [Full Text] [Related]
12. New drugs for chronic lymphocytic leukemia.
Byrd J
Clin Adv Hematol Oncol; 2006 Mar; 4(3):183-5. PubMed ID: 16728926
[No Abstract] [Full Text] [Related]
13. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z
Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061
[TBL] [Abstract][Full Text] [Related]
15. Editorial: the importance of rational chemotherapy of chronic lymphocytic leukemia.
Podhorecka M; Bozko P
Curr Pharm Des; 2012; 18(23):3321-2. PubMed ID: 22591388
[No Abstract] [Full Text] [Related]
16. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.
Cheson BD; Byrd JC; Rai KR; Kay NE; O'Brien SM; Flinn IW; Wiestner A; Kipps TJ
J Clin Oncol; 2012 Aug; 30(23):2820-2. PubMed ID: 22778323
[No Abstract] [Full Text] [Related]
17. [Recent progress in prognostic markers and treatment of chronic lymphocytic leukemia].
Kowal M
Pol Arch Med Wewn; 2006 Sep; 116(3):888-95. PubMed ID: 18652284
[No Abstract] [Full Text] [Related]
18. Chronic lymphocytic leukemia: a niche for flavopiridol?
Brown JR
Clin Cancer Res; 2005 Jun; 11(11):3971-3. PubMed ID: 15930331
[No Abstract] [Full Text] [Related]
19. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with theophylline in chronic lymphocytic leukemia.
Ural AU
Haematologia (Budap); 2001; 31(1):85-6. PubMed ID: 11345411
[No Abstract] [Full Text] [Related]
[Next] [New Search]
